Fig. 5From: Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogressionMaximum Intensity Projected Ga-68 DOTATATE PET Images of representative patient. Increase in metastatic lesion uptake post 30 mg Sandostatin LAR in the setting of decreasing serum chromogranin levels and no change in anatomic size of lesions suggests altered DOTATATE biodistribution following SSA resulting in pseudoprogression. Also note diffusely decreased thyroid uptake, which is almost universally seen in all patients following SSABack to article page